Deutetrabenazine
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Deutetrabenazine |
| DrugBank ID | DB12161 |
| Brand Names (EU) | Austedo |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.73% |
Approved Indication (EMA)
Treatment of moderate to severe tardive dyskinesia in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | psychogenic movement disorders | 98.73% | DL |
| 2 | tremor-nystagmus-duodenal ulcer syndrome | 98.70% | DL |
| 3 | primary orthostatic tremor | 98.68% | DL |
| 4 | benign paroxysmal tonic upgaze of childhood with ataxia | 98.59% | DL |
| 5 | chronic tic disorder | 98.31% | DL |
| 6 | extrapyramidal and movement disease | 98.26% | DL |
| 7 | benign shuddering attacks | 98.26% | DL |
| 8 | polycystic kidney disease 3 with or without polycystic liver disease | 97.88% | DL |
| 9 | acute intermittent porphyria | 97.73% | DL |
| 10 | Hirschsprung disease | 97.60% | DL |
| 11 | lingual-facial-buccal dyskinesia | 97.41% | DL |
| 12 | renal-hepatic-pancreatic dysplasia | 97.25% | DL |
| 13 | miscellaneous movement disorder due to neurodegenerative disease | 97.16% | DL |
| 14 | karyomegalic interstitial nephritis | 96.96% | DL |
| 15 | Joubert syndrome with renal defect | 96.79% | DL |
| 16 | thoracic malformation | 96.59% | DL |
| 17 | adult familial nephronophthisis-spastic quadriparesia syndrome | 96.45% | DL |
| 18 | Huntington disease-like syndrome due to C9ORF72 expansions | 95.56% | DL |
| 19 | juvenile Huntington disease | 95.02% | DL |
| 20 | glutaric acidemia type 3 | 94.55% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.